Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
E-series prostaglandins (PGs) inhibit
glucagon
-stimulated cyclic AMP accumulation in hepatocytes as well as
glucagon
-stimulated glycogenolysis and fatty acid oxidation. The present study was designed to test the hypothesis that this inhibition occurs via interactions with a plasma membrane PGE2 receptor coupled to adenylate cyclase. PGE2 receptors in rat liver plasma membranes were examined using competitive binding studies [( 3H]PGE2 vs. PGE1). Binding data were analyzed to determine the number of apparent binding sites and the PGE dissociation constant (Kd) at each site. Rat liver plasma membranes contained two classes of binding sites with Kd values of 9.9 X 10(-10) and 8 X 10(-9) M. Addition of the GTP-analog guanyl-5'-6'-imidodiphosphate (0.1 mM) altered the PGE2 binding such that a single class of sites with low affinity (Kd = 4 X 10(-9) M) was observed. Similarly, liver plasma membranes isolated from rats pretreated with pertussis toxin contained only a single class of PGE2 binding sites in the absence of guanyl-5'-6'-imidodiphosphate (Kd = 3.4 X 10(-9) M). PGE2 (10(-10) M) inhibited liver membrane adenylate cyclase activity stimulated by forskolin (by 57%) and
glucagon
(by 24%). This inhibition was not observed in membranes isolated from rats treated with pertussis toxin. Thus, the present studies demonstrate that PGE binding to its hepatic receptors is regulated by a pertussis toxin sensitive
guanine nucleotide binding protein
coupled to inhibition of adenylate cyclase.
...
PMID:Coupling of hepatic prostaglandin receptors to adenylate cyclase through a pertussis toxin sensitive guanine nucleotide regulatory protein. 253 66
The effect of muscarinic agonist on adenylate cyclase was investigated in neonatal islet cells and in a clonal pituitary cell line (GH4C1) following labelling of the intracellular ATP pool with [2,8 3H]adenine. In islet cells carbamylcholine was without effect on basal or
glucagon
-stimulated adenylate cyclase activity, measured as 3H cyclic AMP production, but inhibited 3H cyclic AMP production in the clonal pituitary cells. The involvement of the inhibitory
guanine nucleotide binding protein
of adenylate cyclase (Ni) was investigated by the use of the Bordetella pertussis exotoxin, islet activating protein (IAP). Pre-treatment of islet cells with IAP was without effect on adenylate cyclase following carbamylcholine but in the clonal pituitary line abolished the inhibition of 3H cyclic AMP production. It is concluded that in the islet cell, in contrast to the clonal pituitary cell, muscarinic receptors are not effectively coupled through Ni to inhibit adenylate cyclase.
...
PMID:Evidence that muscarinic receptors in islet cells are not coupled functionally to adenylate cyclase through the inhibitory guanine nucleotide binding protein (Ni). 313 98
Liver plasma membrane adenylate cyclase was stimulated paradoxically by an alpha 2-adrenergic mechanism under conditions of low metal ion and low GTP concentrations. In untreated membranes, epinephrine stimulation was GTP-dependent and was mediated by beta-adrenergic receptors since it was completely blocked by propranolol, but unaffected by dihydroergocryptine. Pre-treatment of membranes to remove or reduce divalent cations and guanine nucleotides changed epinephrine stimulation to a form that was mediated by alpha 2-receptors since it was completely blocked by dihydroergocryptine, phenoxybenzamine and yohimbine, but not by propranolol or prazosin. The pre-treatment did not alter enzyme activation by isoproterenol or
glucagon
, alpha 2-Adrenergic stimulation of adenylate cyclase in depleted membranes required the presence in the assay of 1-2 mM Mg2+ and small amounts of exogenous GTP (less than or equal to 50 nM). Increasing the Mg2+ or GTP concentration in the assay produced a progressive reversal of epinephrine-stimulated activity from an alpha 2-adrenergic form to a predominantly beta-adrenergic form. Readdition of Ca2+ or Mg2+, but not Mn2+, into depleted membranes by incubation in the presence of metal reestablished the pattern of enzyme sensitivity to epinephrine to that seen with untreated membranes i.e., it changed from alpha 2- to beta-receptor mediation. Alterations in membrane and assay content of metal ions and GTP did not result in the activation of the enzyme by vasopressin or angiotensin II. These findings demonstrate the ability of Ca2+, Mg2+ and GTP to control the coupling of beta- and alpha 2-adrenergic receptors with liver adenylate cyclase. It is hypothesized that the cations act by regulating the interaction of the receptors with adrenergic agonists and/or the
guanine nucleotide binding protein
(s) which is postulated to be involved in control of the enzyme.
...
PMID:Regulation of adrenergic stimulation of hepatic adenylate cyclase by divalent cations. 627 6
Growth hormone-releasing hormone (GHRH) belongs to the family of gut-neuropeptide hormones which also includes
glucagon
, secretin and vasoactive intestinal peptide (VIP). All receptors for this peptide hormone family seem to involve similar signal transduction pathways. Upon hormone binding, these receptors interact with
guanine nucleotide binding protein
'Gs' and cause the stimulation of adenylate cyclase. The secretin and VIP receptor cDNAs have recently been cloned and found to be homologous to those of calcitonin and parathyroid hormone receptors. Based on cDNA sequences of these receptors, we designed several oligonucleotide primers which were used to amplify two novel porcine pituitary cDNA fragments by the polymerase chain reaction. One novel receptor cDNA fragment was used to screen a porcine pituitary cDNA library and a full-length cDNA encoding a putative porcine GHRH receptor of 451 amino acids was isolated. This putative receptor mRNA is present specifically in porcine anterior pituitary cells and not in eight other porcine tissues as shown by Northern hybridization analysis. The receptor cDNA was subsequently cloned into a mammalian cell expression vector containing the cytomegalovirus promoter. A human kidney tumor cell line (293) stably transfected with this vector was found to express the receptor efficiently and to bind [125I]-GHRH specifically. Furthermore, challenge of the 293 cells expressing the receptor by GHRH leads to efficient stimulation of cytoplasmic cAMP production.
...
PMID:Structure and functional expression of a complementary DNA for porcine growth hormone-releasing hormone receptor. 841 47
Glucagon-like peptide 1
is a gastrointestinally derived hormone with profound effects on nutrient-induced pancreatic hormone release. GLP-1 modulates insulin,
glucagon
and somatostatin secretion by binding to
guanine nucleotide binding protein
-coupled receptors resulting in the activation of adenylate cyclase and generation of cyclic adenosine monophosphate (cAMP). In the B-cell, cAMP, via activation of protein kinase A, interacts with a plethora of signal transduction processes including ion channel activity, intracellular Ca2+ handling and exocytosis of the insulin-containing granules. The stimulatory action of GLP-1 on insulin secretion, contrary to that of the currently used hypoglycaemic sulphonylureas, is glucose dependent and requires the presence of normal or elevated concentrations of the sugar. For this reason, GLP-1 attracts much interest as a possible novel principle for the treatment of human type-2 diabetes. Here we review the actions of GLP-1 on islet cell function and attempt to integrate current knowledge into a working model for the control of pancreatic hormone secretion.
...
PMID:Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. 947 10